Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma

Carcinogenesis

Volumn 27, Issue 9, 2006, Pages 1828-1834

  Wang, Sophia S ^e   Davis, Scott ^a   Cerhan, James R ^b,f   Hartge, Patricia ^e   Severson, Richard K ^c   Cozen, Wendy ^d   Lan, Qing ^e   Welch, Robert ^e   Chanock, Stephen J ^e   Rothman, Nathaniel ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Mayo Clinic   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYGUANINE DNA GLYCOSYLTRANSFERASE; ALANINE; ALDOKETOREDUCTASE A1; ALDOKETOREDUCTASE C1; CYTOCHROME B; CYTOCHROME B 245 ALPHA; DNA; DNA GLYCOSYLTRANSFERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE PEROXIDASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUCINE; MANGANESE SUPEROXIDE DISMUTASE; MYELOPEROXIDASE; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; SERINE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RISK; CARCINOGENESIS; CELL LINEAGE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; FOLLICULAR LYMPHOMA; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INFLAMMATION; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LYMPHOMA;

ADULT; AGED; CASE-CONTROL STUDIES; DNA REPAIR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NF-KAPPA B; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REACTIVE OXYGEN SPECIES; RISK;

EID: 33747014907     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl013     Document Type: Article

References (49)

1. Chang,C.L., Marra,G., Chauhan,D.P. et al. (2002) Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell Physiol., 283, C148-C154.
2. Hussain,S.P., Hofseth,L.J. and Harris,C.C. (2003) Radical causes of cancer. Nat. Rev. Cancer, 3, 276-285.
3. Marrogi,A.J., Khan,M.A., van Gijssel,H.E. et al. (2001) Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. J. Natl Cancer Inst., 93, 1652-1655.
4. Bewick,M., Coutie,W. and Tudhope,G.R. (1987) Superoxide dismutase, glutathione peroxidase and catalase in the red cells of patients with malignant lymphoma. Br. J. Haematol., 65, 347-350.
5. Li,H.L., Sun,B.Z. and Ma,F.C. (2004) Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J. Gastroenterol., 10, 1862-1866.
6. Mendes,R.V., Martins,A.R., de Nucci,G., Murad,F. and Soares,F.A. (2001) Expression of nitric oxide synthase isoforms and nitrotyrosine immunoreactivity by B-cell non-Hodgkin's lymphomas and multiple myeloma. Histopathology, 39, 172-178.
7. Abdel-Aziz,A.F. and El Naggar,M.M. (1997) Superoxide dismutase activities in serum and white blood cells of patients with some malignancies. Cancer Lett., 113, 61-64.
8. Li,H., Kantoff,P.W., Giovannucci,E. et al. (2005) Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res., 65, 2498-2504.
9. Stubbins,M.J. and Wolf,C.R. (1999) Additional polymorphisms and cancer. IARC Sci. Publ., 148, 271-302.
10. Krajinovic,M., Sinnett,H., Richer,C., Labuda,D. and Sinnett,D. (2002) Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int. J. Cancer, 97, 230-236.
11. Nauseef,W.M. (2001) Contributions of myeloperoxidase to proinflammatory events: More than an antimicrobial system. Int. J. Hematol, 74, 125-133.
12. Shimoda-Matsubayashi,S., Matsumine,H., Kobayashi,T., Nakagawa-Hattori,Y., Shimizu,Y. and Mizuno,Y. (1996) Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. Biochem. Biophys. Res. Commun., 226, 561-565.
13. Van Remmen,H., Ikeno,Y., Hamilton,M. et al. (2003) Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol. Genomics, 16, 29-37.
14. Chatterjee,N., Hartge,P., Cerhan,J.R. et al. (2004) Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol. Biomarkers Prev., 13, 1415-1421.
15. Bhatti,P., Sigurdson,A.J., Wang,S.S. et al. (2005) Genetic variation and willingness to participate in epidemiologic research: Data from three studies. Cancer Epidemiol. Biomarkers Prev., 14, 2449-2453.
16. Harris,N.L., Jaffe,E.S., Stein,H. et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
17. Garcia-Closas,M., Egan,K.M., Abruzzo,J. et al. (2001) Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol. Biomarkers Prev., 10, 687-696.
18. Packer,B.R., Yeager,M., Staats,B. et al. (2004) SNP500Cancer: A public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res., 32(Database issue), 528-532.
19. Marchini,J., Cardon,L.R., Phillips,M.S. and Donnelly,P. (2004) The effects of human population structure on large genetic association studies. Nat. Genet., 36, 512-517.
20. Benjamini,Y. and Hochberg,Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B, 57, 289-300.
21. Wacholder,S., Chanock,S., Garcia-Closas,M., El Ghormli,L. and Rothman,N. (2004) Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J. Natl Cancer Inst., 96, 434-442.
22. Shen,J., Wang,R.T., Wang,L.W., Xu,Y.C. and Wang,X.R. (2004) A novel genetic polymorphism of inducible nitric oxide synthase is associated with an increased risk of gastric cancer. World J. Gastroenterol., 10, 3278-3283.
23. Stuehr,D.J. (1999) Mammalian nitric oxide synthases. Biochim. Biophys. Acta, 1411(2-3), 217-230.
24. Hussain,S.P., Trivers,G.E., Hofseth,L.J. et al. (2004) Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res., 64, 6849-6853.
25. Mori,M. and Gotoh,T. (2004) Arginine metabolic enzymes, nitric oxide and infection. J. Nutr., 134(Suppl. 10), 2820S-2825S.
26. Sonoki,T., Matsuzaki,H., Nagasaki,A. et al. (1999) Detection of inducible nitric oxide synthase (iNOS) mRNA by RT-PCR in ATL patients and HTLV-I infected cell lines: Clinical features and apoptosis by NOS inhibitor. Leukemia, 13, 713-718.
27. Yan,L., Wang,S., Rafferty,S.P., Wesley,R.A. and Danner,R.L. (1997) Endogenously produced nitric oxide increases tumor necrosis factor-alpha production in transfected human U937 cells. Blood, 90, 1160-1167.
28. Rothman,N., Skibola,C., Wang,S.S. et al. (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncology, 7, 27-38.
29. Marletta,M.A. (1993) Nitric oxide synthase: Function and mechanism. Adv. Exp. Med. Biol., 338, 281-284.
30. Suresh,A., Guedez,L., Moreb,J. and Zucali,J. (2003) Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment. Br. J. Haematol., 120, 457-463.
31. Sutton,A., Imbert,A., Igoudjil,A. et al. (2005) The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics, 15, 311-319.
32. Sutton,A., Khoury,H., Prip-Buus,C., Cepanec,C., Pessayre,D. and Degoul,F. (2003) The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics, 13, 145-157.
33. Olson,S.H., Carlson,M.D., Ostrer,H. et al. (2004) Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol. Oncol., 93, 615-620.
34. Millikan,R.C., Player,J., de Cotret,A.R. et al. (2004) Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. Breast Cancer Res., 6, R264-R274.
35. Hung,R.J., Boffetta,P., Brennan,P. et al. (2004) Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis, 25, 973-978.
36. Gaudet,M.M., Gammon,M.D., Santella,R.M. et al. (2005) MnSOD Val-9Ala genotype, pro- and anti-oxidant environmental modifiers, and breast cancer among women on Long Island, New York. Cancer Causes Control, 16, 1225-1234.
37. Ambrosone,C.B., Ahn,J., Singh,K.K. et al. (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res., 65, 1105-1111.
38. Egan,K.M., Thompson,P.A., Titus-Ernstoff,L., Moore,J.H. and Ambrosone,C.B. (2003) MnSOD polymorphism and breast cancer in a population-based case-control study. Cancer Lett., 199, 27-33.
39. Kocabas,N.A., Sardas,S., Cholerton,S., Daly,A.K., Elhan,A.H. and Karakaya,A.E. (2005) Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. Cell Biochem. Funct., 23, 73-76.
40. Lin,P., Hsueh,Y.M., Ko,J.L., Liang,Y.F., Tsai,K.J. and Chen,C.Y. (2003) Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer, 40, 123-129.
41. Mitrunen,K., Sillanpaa,P., Kataja,V. et al. (2001) Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis, 22, 827-829.
42. Wang,L.I., Neuberg,D. and Christiani,D.C. (2004) Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. J. Occup. Environ. Med., 46, 556-564.
43. Woodson,K., Tangrea,J.A., Lehman,T.A. et al. (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control., 14, 513-518.
44. Abou-Seif,M.A., Rabia,A. and Nasr,M. (2000) Antioxidant status, erythrocyte membrane lipid peroxidation and osmotic fragility in malignant lymphoma patients. Clin. Chem. Lab. Med., 38, 737-742.
45. Van Schooten,F.J., Boots,A.W., Knaapen,A.M. et al. (2004) Myeloperoxidase (MPO) -463G→A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol. Biomarkers Prev., 13, 828-833.
46. Piedrafita,F.J., Molander,R.B., Vansant,G., Orlova,E.A., Pfahl,M. and Reynolds,W.F. (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J. Biol. Chem., 271, 4412-14420.
47. Feyler,A., Voho,A., Bouchardy,C. et al. (2002) Point: Myeloperoxidase 463G→A polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 11, 1550-1554.
48. Ray,D.M., Akbiyik,F., Bernstein,S.H. and Phipps,R.P. (2005) CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism. J. Immunol., 174, 4060-4069.
49. Duan,S.Z., Ivashchenko,C.Y., Russell,M.W., Milstone,D.S. and Mortensen,R.M. (2005) Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ. Res., 97, 372-379.